Answers to frequently asked questions about migraine

Mayo Clinic Proceedings

Volumn 81, Issue 10, 2006, Pages 1387-1392

  Garza, Ivan ^a   Swanson, Jerry W ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISABILITY; ECONOMIC ASPECT; HEADACHE; HUMAN; MIGRAINE; PROPHYLAXIS; SHORT SURVEY; TREATMENT PLANNING;

EID: 33749265461     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/81.10.1387     Document Type: Review

References (31)

1. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41:646-657.
2. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24(suppl 1):25-36.
3. Lipton RB, Stewart WF, Simon D. Medical consultation for migraine: results from the American Migraine Study. Headache. 1998;38:87-96.
4. Tepper SJ, Dahlof CG, Dowson A, et al. Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: data from the Landmark Study. Headache. 2004;44:856-864.
5. Dodick DW. Diagnosing headache: clinical clues and clinical rales. Adv Stud Med. 2003;3:87-92.
6. Dahlof CG, Solomon GD. The burden of migraine to the individual sufferer: a review. Eur J Neurol. 1998;5:525-533.
7. Lipton RB, Dodick D, Sadovsky R, et al. A self-administered screener for migraine in primary care: The ID Migraine validation study. Neurology. 2003;61:375-382.
8. Mathew NT, Loder EW. Evaluating the triptans. Am J Med. 2005;118(suppl 1):28S-35S.
9. Rapoport AM, Tepper SJ, Sheftell FD, Kung E, Bigal ME. Which triptan for which patient? Neurol Sci. 2006;27(suppl 2):S123-S129.
10. Dodick DW. Triptan nonresponder studies: implications for clinical practice. Headache. 2005;45:156-162.
11. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol. 2000;47:614-624.
12. Mathew NT, Tfelt-Hansen P. General and pharmacologic approach to migraine management. In: Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA, eds. The Headaches. 3rd ed. Philadelphia, Pa: Lippincott Williams and Wilkins; 2006:433-440.
13. Diener HC, Katasarva Z. Analgesic/abortive overuse and misuse in chronic daily headache. Curr Pain Headache Rep. 2001;5:545-550.
14. Smith TR, Stoneman J. Medication overuse headache from antimigraine therapy: clinical features, pathogenesis and management. Drugs. 2004;64:2503-2514.
15. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Available at: www.neurology.org/cgi/content/full/55/6/754. Accessed August 31, 2006.
16. Silberstein SD. Preventive treatment of headaches. Curr Opin Neurol. 2005;18:289-292.
17. Loder E, Biondi D. General principles of migraine management: the changing role of prevention. Headache. 2005;45(suppl 1):S33-S47.
18. Garza I, Swanson JW. Prophylaxis of migraine. Neuropsychiatr Dis Treat. 2006;2(3):281-291.
19. Evers S, Mylecharane EJ. Nonsteroidal anti-inflammatory and miscellaneous drugs in migraine prophylaxis. In: Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA, eds. The Headaches. 3rd ed. Philadelphia, Pa: Lippincott Williams and Wilkins; 2006:553-566.
20. Ramadan NM. Prophylactic migraine therapy: mechanisms and evidence. Curr Pain Headache Rep. 2004;8:91-95.
21. D'Amico D. Treatment strategies in migraine patients. Neurol Sci. 2004;25(suppl 3):S242-S243.
22. Allais G, Bussone G, De Lorenzo C, Mana O, Benedetto C. Advanced strategies of short-term prophylaxis in menstrual migraine: state of the art and prospects. Neurol Sci. 2005;26(suppl 2):S125-S129.
23. Silberstein SD, Saper JR, Freitag FG. Migraine: diagnosis and treatment. In: Silberstein SD, Lipton RB, Dalessio DJ, eds. Wolffs Headache and Other Head Pain. 7th ed. New York, NY: Oxford University Press; 2001:121-237.
24. Newman LC, Lipton RB, Lay CL, Solomon S. A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine. Neurology. 1998;51:307-309.
25. Newman L, Mannix LK, Landy S, et al. Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. Headache. 2001;41:248-256.
26. Silberstein SD, Elkind AH, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology. 2004;63:261-269.
27. Silberstein SD, Dodick D, Kesslick J. Removing barriers to appropriate migraine treatment: formulary limitations and triptan package size. Headache. 2005;45:1250-1254.
28. Massiou H, MacGregor EA. Evolution and treatment of migraine with oral contraceptives. Cephalalgia. 2000;20:170-174.
29. Evans RW, Lipton RB. Topics in migraine management: a survey of headache specialists highlights some controversies. Neurol Clin. 2001;19:1-21.
30. Mathew NT, Kurman R, Perez F. Drug induced refractory headache-clinical features and management. Headache. 1990;30:634-638.
31. Evans RW, Loder E, Biondi DM. When can successful migraine prophylaxis be discontinued? Headache. 2004;44:1040-1042.